Correction: Interim Report for Ortivus AB (publ) for the period January – March 2025
2025-05-09 08:35
The correction concerns the omission of a reference to the Market Abuse Regulation (MAR).
“Our ambition is not only to deliver technology, but to be a strategic partner in the transformation of healthcare.”
January – March 2025
- Net sales decreased by 18% and amounted to SEK 18.1 million (22.1).
- The gross margin increased to 42% (41%).
- EBITDA amounted to SEK -1.1 million (-1.0).
- Profit after tax was SEK -2.5 million (-2.2).
- Earnings per share before and after dilution amounted to SEK -0.06 (-0.05).
- Cash flow from operating activities amounted to SEK -4.8 million (-6.4).
Significant events during and after the reporting period
During the quarter, an agreement was signed with a new customer, East Midlands Ambulance Service NHS Trust (EMAS). The agreement strengthens Ortivus’ presence in the UK and concerns the delivery of a digital system for the management of controlled drugs. The agreement runs for a minimum of three years and is expected to generate just over SEK 3.6 million in revenue.
At the end of April, Ortivus hosted the annual international user forum in Birmingham. Attendance was higher than ever before, reflecting the growing interest in our initiatives within iOS, cloud-based solutions, cybersecurity, and more efficient data capture.
Ortivus AB has convened its Annual General Meeting for Thursday, 8 May 2025.